360 MASSACHUSETTS AVENUE, SUITE 203, ACTON, MA
Announce Partnership to Expand Access to U.S. Federal Healthcare Markets
Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization
Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study
Annual Meeting Held; Stockholders Approve Amendment to Stock Plan
Announces Closing of Up to $23.7 Million Private Placement Priced at-the-market Under Nasdaq Rules
Announce Strategic Partnership
Provides First Quarter 2026 Corporate Update
Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial
Q2
Q1
FY 2025
Q3
Amended Annual Report
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload
Prospectus Filed Pursuant to Rule 424(b)(1)